Souhaitez-vous accéder aux communiqués récents ?

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026

Schaumburg, IL, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Dermatologic Surgery, the official scientific journal of the American Society for Dermatologic Surgery (ASDS), has published a special issue on...

CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.

Schaumburg, IL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to introduce its new President, Kavita Mariwalla, MD, who began serving her one-year...

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on...

Austin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Atopic Dermatitis Drugs Market Size & Growth Analysis According to by SNS Insider, the Atopic Dermatitis Drugs Market size was valued at USD 14.93...

InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...